Bristol-Myers’ Sprycel (dasatinib) Receives CHMP Recommendation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL)

 Bristol-Myers’ Sprycel (dasatinib) Receives CHMP Recommendation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL)

Bristol-Myers’ Sprycel (dasatinib) Receives CHMP Recommendation for Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (ALL)

Shots:
  • The CHMP (EMA) recommendation is based on P-II CA180-372 (NCT01460160) study assessing Sprycel + CT in pediatric patients with newly diagnosed +ve acute lymphoblastic leukemia (ALL)
  • Sprycel received the US FDA’s and EU’s approval to treat pediatric patients with +ve chronic myeloid leukemia in chronic phase (CML-CP) in Nov, 2017 & July, 2018 respectively
  • Sprycel is a tyrosine kinase inhibitor, approved by the US FDA for philadelphia chromosome +ve CML-CP for adults

Click here to read full press release/ article | Ref: Bristol-Myers Squibb | Image: Alamy

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post